Clinical Trial Update: Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

An open-label extension study evaluating safety and tolerability of AAB-003 (PF-05236812) in adults with mild to moderate Alzheimer's disease has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AAB-003 (PF-05236812) (PF-05236812)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2017-03-10